The median PFS was 5.3 and 4.7 (95% CI 3.2–5.3) months in the nab-PTX + RAM and PTX + RAM groups, respectively. In total, 190 (72%) patients were matched. Progression-free survival (PFS), overall survival (OS), and toxicity were compared using 1:1 propensity score matching. Nab-PTX was administered at dosages of 100 mg/m 2, replacing PTX in the standard PTX + RAM regimen. MethodsĬlinical data of 265 patients treated for AGC with nab-PTX + RAM or PTX + RAM were retrospectively collected. Here, we compared the efficacy and toxicity of nab-PTX + RAM and PTX + RAM using propensity score matching. Although some retrospective and single-arm phase II studies regarding nab-PTX + RAM have been reported, comparative studies are lacking. Nanoparticle albumin-bound paclitaxel (nab-PTX) is an improved, more convenient form of PTX and is non-inferior to PTX. Paclitaxel plus ramucirumab (PTX + RAM) is the standard second-line chemotherapy for unresectable advanced or recurrent gastric cancer (AGC).
0 Comments
Leave a Reply. |